These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31629010)

  • 1. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA; Fletcher PJ; Shanahan WR
    Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.
    Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1071-88. PubMed ID: 25870913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.
    Higgins GA; Silenieks LB; Altherr EB; MacMillan C; Fletcher PJ; Pratt WE
    Psychopharmacology (Berl); 2016 Jul; 233(14):2841-56. PubMed ID: 27241709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM; Berlie HD
    Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of impulsivity and reward in the anti-obesity actions of 5-HT
    Higgins GA; Zeeb FD; Fletcher PJ
    J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
    [No Abstract]   [Full Text] [Related]  

  • 9. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA; Sellers EM; Fletcher PJ
    Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACS chemical neuroscience molecule spotlight on Lorcaserin.
    Hopkins CR
    ACS Chem Neurosci; 2010 Nov; 1(11):718-9. PubMed ID: 22778808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lorcaserin Hcl for the treatment of obesity.
    Shukla AP; Kumar RB; Aronne LJ
    Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
    Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ
    Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directly Observable Behavioral Effects of Lorcaserin in Rats.
    Serafine KM; Rice KC; France CP
    J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 5-HT
    Higgins GA; Brown M; St John J; MacMillan C; Silenieks LB; Thevarkunnel S
    Neuropharmacology; 2020 Jun; 170():108064. PubMed ID: 32222404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.
    Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW
    Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
    Hurren KM; Dunham MW
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evidence for combining the 5-HT
    Fletcher PJ; Li Z; Silenieks LB; MacMillan C; DeLannoy I; Higgins GA
    Addict Biol; 2019 May; 24(3):376-387. PubMed ID: 29498158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.